Integrative network pharmacology and molecular modeling approaches reveal the therapeutic potential of Syzygium samarangense phytocompounds against diabetes retinopathy
Aug 2026· Frontiers in Bioinformatics· Vol 6· 0 citations· 60 references
Medicine
TL;DR
These multi-target interactions suggest that S. samarangense phytochemicals can modulate key DR-associated pathways, and exhibits promising multi-target activity against Diabetes retinopathy.
Abstract
Introduction Diabetes retinopathy (DR) is a progressive microvascular complication of diabetes mellitus characterized by oxidative stress, inflammation, and neurovascular dysfunction. Current therapies provide limited efficacy, highlighting the need for multi-targeted, natural therapeutic alternatives. Syzygium samarangense (SS) is a phytochemical-rich medicinal plant with potential anti-Diabetes properties. Methodology A data-driven systems pharmacology approach was employed to explore the anti-DR potential of S. samarangense phytochemicals. Twenty-nine active compounds were screened for drug-likeness using Lipinski’s Rule of Five. Overlapping targets between SS and DR were identified, yielding 403 shared targets. Network pharmacology analysis highlighted ten core proteins, including SRC, ALB, GAPDH, and TNF. Gene Ontology (GO) and KEGG pathway enrichment analyses identified key pathways such as AGE-RAGE and HIF-1 signaling. Molecular docking was performed to evaluate ligand–target interactions, followed by 500 ns molecular dynamics (MD) simulations and MM-GBSA binding free energy analysis for validation. Results and Discussion Docking studies identified Pinocembrin (SS5) and Stercurensin (SS4) as top-ranked ligands, with strong binding affinities toward SRC and ALB, respectively. MD simulations demonstrated superior structural stability for the SS5–SRC complex, whereas SS4–ALB exhibited moderate stability. MM-GBSA calculations further confirmed favorable binding energies, supporting their drug-like behavior. These multi-target interactions suggest that S. samarangense phytochemicals can modulate key DR-associated pathways. Conclusion S. samarangense exhibits promising multi-target activity against Diabetes retinopathy. Pinocembrin (SS5) and Stercurensin (SS4) emerge as potential lead compounds for further experimental validation and drug development.
Findings position SRR as a hypothesis‐generating source of multi‐target candidate molecules and provide a prioritized framework for experimental validation in AD.
Archna Singh, Avijit Mazumder, A. Kanda· ChemistrySelect· 0 citations
Evaluated phytoconstituents from Allium cepa, Curcuma longa, and Coleus forskohlii suggest that curcumin, quercetin, and rosmarinic acid are promising multi-target nootropic phytoconstituents with therapeutic potential for the treatment of cognitive impairment.
M. Manke, O. Bhusnure· Genetics and Molecular Resea...· 0 citations
CNZP exhibits significant therapeutic effects on RA, potentially by downregulating NOS1 expression and subsequently correcting the metabolic imbalance of L-arginine, and this preclinical study provides mechanistic evidence for the anti-RA effect of CNZP.
Zhi-Qiang Li, Liang Cao, Jia-Jia Wang et al.· Clinical Rheumatology· 0 citations
This study provides the first systems-level computational evidence for D. cinerea’s multi-target therapeutic potential in AD, establishing a molecular foundation for future experimental validation.
Prabhakar Vengadasamy, A. Vijayalakshmi· Journal of Natural Remedies· 0 citations
BACKGROUND
Rosacea is a chronic inflammatory skin disorder with limited therapeutic options. Puhuaiyin (PHY), a traditional Chinese medicinal formula, shows clinical efficacy, but its multi-component mechanisms remain unclear.
METHODS
Chemical constituents of PHY were identified by UPLC-Q-TOF-MS. Network pharmacology...
Dan Sun, Na-Na Yang, Yi-Ding Zhao et al.· Current Computer - Aided Dru...· 0 citations
It is demonstrated that XTBLD exerts cardioprotective effects against DCM via regulating its key active components, core targets (CDKN1A, IGFBP3), and related signaling pathways, providing a scientific basis for XTBLD's clinical application in DCM management.
Min Wang, Kaijie Xie, Hao Liu et al.· Current pharmaceutical desig...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.